Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07154290 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT07154290 is a Phase 2 study that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 300 participants.
The verdict
NCT07154290, a Phase 2 study, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and REGN7075 works * The side effects that ubamatamab and REGN7075 might cause * How much ubamatamab and REGN7075 is in the blood at different times * If the body makes antibodies to ubamatamab and/or REGN7075, this may cause the ubamatamab to not work as well
Interventions
- DRUG REGN7075
- DRUG Ubamatamab
- DRUG Sarilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2030-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07154290
The ClinicalTrials.gov registry entry for NCT07154290 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which REGN7075 is the first listed.
NCT07154290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07154290 about?
NCT07154290 is a clinical study titled "A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)". This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well u...
What is the current status of trial NCT07154290?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2026-03-18. Estimated completion is 2030-06-24.
What interventions are being tested in trial NCT07154290?
The interventions under investigation include: REGN7075 (DRUG), Ubamatamab (DRUG), Sarilumab (DRUG).
Who is sponsoring clinical trial NCT07154290?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.